ArticleJournal of neuro-oncology2022

Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.

Jan-Michael Werner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.